ERBB2 and breast carcinoma: ST data were collected from two cohorts for breast cancer studies: one cohort (He et al. 2020) contains 68 tissue sections from 23 breast cancer patients with five different molecular subtypes, and the other cohort (Andersson et al. 2021) consists of 36 tissue sections from eight HER2-positive breast cancer patients.